BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 19719389)

  • 21. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
    Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C
    Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
    Sun C; Shou P; Du H; Hirabayashi K; Chen Y; Herring LE; Ahn S; Xu Y; Suzuki K; Li G; Tsahouridis O; Su L; Savoldo B; Dotti G
    Cancer Cell; 2020 Feb; 37(2):216-225.e6. PubMed ID: 32004441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.
    Huang X; Guo H; Kang J; Choi S; Zhou TC; Tammana S; Lees CJ; Li ZZ; Milone M; Levine BL; Tolar J; June CH; Scott McIvor R; Wagner JE; Blazar BR; Zhou X
    Mol Ther; 2008 Mar; 16(3):580-9. PubMed ID: 18227839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
    Imai C; Mihara K; Andreansky M; Nicholson IC; Pui CH; Geiger TL; Campana D
    Leukemia; 2004 Apr; 18(4):676-84. PubMed ID: 14961035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors.
    Muliaditan T; Halim L; Whilding LM; Draper B; Achkova DY; Kausar F; Glover M; Bechman N; Arulappu A; Sanchez J; Flaherty KR; Obajdin J; Grigoriadis K; Antoine P; Larcombe-Young D; Hull CM; Buus R; Gordon P; Grigoriadis A; Davies DM; Schurich A; Maher J
    Cell Rep Med; 2021 Dec; 2(12):100457. PubMed ID: 35028604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells.
    Wijewarnasuriya D; Bebernitz C; Lopez AV; Rafiq S; Brentjens RJ
    Cancer Immunol Res; 2020 Jun; 8(6):732-742. PubMed ID: 32213625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
    Carpenito C; Milone MC; Hassan R; Simonet JC; Lakhal M; Suhoski MM; Varela-Rohena A; Haines KM; Heitjan DF; Albelda SM; Carroll RG; Riley JL; Pastan I; June CH
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3360-5. PubMed ID: 19211796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells.
    Kim YJ; Brutkiewicz RR; Broxmeyer HE
    Blood; 2002 Nov; 100(9):3253-60. PubMed ID: 12384425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
    J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.
    Saoulli K; Lee SY; Cannons JL; Yeh WC; Santana A; Goldstein MD; Bangia N; DeBenedette MA; Mak TW; Choi Y; Watts TH
    J Exp Med; 1998 Jun; 187(11):1849-62. PubMed ID: 9607925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.
    Cappell KM; Kochenderfer JN
    Nat Rev Clin Oncol; 2021 Nov; 18(11):715-727. PubMed ID: 34230645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
    Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
    Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
    Zhong XS; Matsushita M; Plotkin J; Riviere I; Sadelain M
    Mol Ther; 2010 Feb; 18(2):413-20. PubMed ID: 19773745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.
    Wang X; Wong CW; Urak R; Mardiros A; Budde LE; Chang WC; Thomas SH; Brown CE; La Rosa C; Diamond DJ; Jensen MC; Nakamura R; Zaia JA; Forman SJ
    Clin Cancer Res; 2015 Jul; 21(13):2993-3002. PubMed ID: 25838392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics.
    Zhong Q; Zhu YM; Zheng LL; Shen HJ; Ou RM; Liu Z; She YL; Chen R; Li C; Huang J; Yao MD; Zhang Q; Liu S
    Acta Haematol; 2018; 140(3):131-140. PubMed ID: 30253384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
    Savoldo B; Ramos CA; Liu E; Mims MP; Keating MJ; Carrum G; Kamble RT; Bollard CM; Gee AP; Mei Z; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Dotti G
    J Clin Invest; 2011 May; 121(5):1822-6. PubMed ID: 21540550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.